Two for the heart: Dutch Pharmacogenetic Working Group prescribing guidance on statins and sulfonylureas to reduce cardiometabolic risk
- PMID: 39910330
- PMCID: PMC11986010
- DOI: 10.1038/s41431-025-01796-y
Two for the heart: Dutch Pharmacogenetic Working Group prescribing guidance on statins and sulfonylureas to reduce cardiometabolic risk
Conflict of interest statement
Competing interests: The author declares no competing interests.
Comment on
-
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas.Eur J Hum Genet. 2025 Apr;33(4):413-420. doi: 10.1038/s41431-024-01769-7. Epub 2024 Dec 15. Eur J Hum Genet. 2025. PMID: 39676086
References
-
- World-Health-Organization. The top ten causes of death. Accessed 10/01/2025, 2024. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-de....
-
- Chou R, Cantor A, Dana T, Wagner J, Ahmed AY, Fu R, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2022;328:754–71. 10.1001/jama.2022.12138. - PubMed
-
- Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenom J. 2010;10:1–11. 10.1038/tpj.2009.54. - PubMed
Publication types
Grants and funding
- R13 CA101634/CA/NCI NIH HHS/United States
- R21 HG013413/HG/NHGRI NIH HHS/United States
- R21HG013413/U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI)
- UL1TR002389/U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (NCATS)
- R01 DA017441/DA/NIDA NIH HHS/United States
LinkOut - more resources
Full Text Sources
